A Phase 4 interventional study of Anakinra 100 mg in 2 ml saline IA in Knee Injuries, sponsored by Oslo University Hospital. Withdrawn at 1 site in Norway. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-06-11.
Sponsored by Oslo University Hospital · Phase 4, Interventional, and Treatment
This project investigates the relation between acute pain and local inflammation. Pain reported by the patients for knee arthroscopy are compared with local changes in inflammatory mediators by using microdialysis technique. Patients with moderate-to-severe pain are included in a randomized placebo-controlled trial of anakinra given intra-articularly.
The effects of the recombinant IL-1 receptor antagonist anakinra both on acute pain and post operative inflammation will be evaluated. On inclusion, pain intensity will be measured on a five-point verbal rating scale (0= no pain, 1=mild pain, 2=moderate pain, 3=severe pain, and 4=intolerable pain), and on a visual analogue scale (0-100mm). VAS scale will be repeated at 20, 40, 60, 80, 100, 120, 140, 160, 180 and 200 minutes after inclusion / intervention. The patients will also rate pain intensity during a 5 meters walk at 200 minutes (evoked pain). The patient will rate pain at rest and evoked pain 24, 48 and 72 h after intervention.
249 studies on the registry are indexed under Knee Injuries; 48 are open to participants now.
Browse Knee Injuries studies →Oslo University Hospital is the lead sponsor of 810 studies on the registry; 148 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Anakinra 100 mg in 2 ml saline IA
Drug: Anakinra 100 mg in 2 ml saline IA
Saline 2 ml IA
Drug: Anakinra 100 mg in 2 ml saline IA
Also known as: Kineret
Pain relief
Selv reported pain
Time frame: 72h
Resuce analgesic drug consumption
Need for and consumption of resuce analgesic drug
Time frame: 72h
Side effects
Selv reported side effect according to CRF
Time frame: 72h
This study is withdrawn, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Oslo University Hospital